TPO and autoimmune polyendocrinopathy: Early case reports and case series describing the use of TPO mimetics in SLE patients, including those with APS, largely showed that these agents were effective and safe without significant risks, and especially for thrombosis.[3,7–10] More recently, several reports have noted potential thrombotic risks of these agents in SLE patients, particularly those with APLA.[5,6,11–15]